In lung cancer patients, ALK gene amplification, mutation, and rearrangement is known to be associated with tumor development [88,89,90], and around 5% of NSCLC cases are diagnosed with an ALK gene rearrangement [90]. This evidence concerns the gene ALK and neoplasm.